Πέμπτη 19 Οκτωβρίου 2017

CTD^2: Bridging Genomics to Therapeutics

The Cancer Target Discovery and Development (CTD^2) initiative was established by the National Cancer Institute (NCI) to bridge the gap between cancer genomics and precision oncology and has developed many approaches for identifying therapeutic targets, perturbagens, and biomarkers. CTD^2 is currently exploring cancer heterogeneities and developing strategies to overcome treatment resistance.



http://ift.tt/2xRLF2u

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου